Skip to main content
TipRanks
Go Ultimate75% OFF

NeoGenomics (NG9) Stock Price & Analysis

0 Followers

NG9 Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 1.66B
Enterprise Value
CHF 2.67B
Total Cash (Recent Filing)
CHF 139.28M
Total Debt (Recent Filing)
CHF 449.14M
Price to Earnings (P/E)
―
Beta
1.58
Next Earnings
Feb 23, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

NGS-led Growth

Rapid NGS growth supported by new products, increasing large-panel volumes and demand across multiple oncology applications indicates durable expansion potential. Its higher-value mix can lift average pricing and strengthen NeoGenomics’ position as testing increasingly shifts toward advanced genomic diagnostics.

Margin And EBITDA Improvement

Meaningful gross-margin expansion alongside strong EBITDA growth shows that revenue gains are converting more effectively into operating profit. The improvement reflects pricing, richer NGS mix and laboratory efficiencies, supporting a more scalable business model if these drivers persist.

Expanding MRD Reimbursement

Additional Medicare coverage strengthens the commercial foundation for RaDaR ST by improving access to a large patient population and reducing reimbursement uncertainty. Further indications under review could broaden adoption, reinforce the MRD franchise and expand recurring diagnostic demand over time.

Bears Say

Persistent Unprofitability

NeoGenomics has not yet translated its improving revenue, margin and operating trends into positive net earnings. Continued losses reduce retained funding for growth and leave shareholder returns negative, so execution must remain strong for operating improvements to become sustainable profitability.

Negative Free Cash Flow

Minimal operating cash generation and ongoing negative free cash flow indicate that the business is not yet consistently self-funding after investment needs. This limits financial flexibility and increases execution sensitivity if the planned margin improvement or revenue growth takes longer to materialize.

Reimbursement And Legacy Revenue Headwinds

Declining legacy pharma activity and unreimbursed MRD testing create pressure on near-term revenue quality and gross margin. Although newer businesses may offset part of the decline, the transition requires NeoGenomics to replace lower-value contracts while expanding reimbursement-supported demand.

NeoGenomics News

NG9 FAQ

What is NeoGenomics’s market cap?
NeoGenomics’s market cap is CHF1.66B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s next earnings report is estimated for Feb 23, 2027 (not yet confirmed), which is in 97 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Oct 28, 2026. The company reported CHF0.058 earnings per share for the quarter, beating the consensus estimate of CHF0.045 by CHF0.012.
Is NeoGenomics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.06.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 129,389,470 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of CHF0.058 in its last earnings report, beating expectations of CHF0.045. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of NeoGenomics?
Hedge funds hold NeoGenomics shares: the largest hedge-fund position in NeoGenomics is 1,532,297,284 shares, and hedge funds increased their holdings by 885.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology